Pharmaceutical Innovators

Pharmaterials Ltd is a technology driven contract research organisation specialising in the optimisation of drug substance physical forms and formulations to facilitate the development of low solubility and poorly permeable drug substances and drug delivery to the lung.

Using high-throughput screening technologies in both physical form generation and formulation design, we assist biotechnology and pharmaceutical companies to rapidly and successfuly progress their problematic lead compounds into the clinical phases of development. With partnerships that span the globe, Pharmaterials works with a range of organisations, including start-up, mid-size and multinational companies.

We can assist or manage projects as needed, from bespoke salt selection and polymorphism screening services through to full formulation screening and development programs.

Company History

Pharmaterials was founded in January 2000 by Professor Graham Buckton as a spin-out company from the London School of Pharmacy, UK. Since inception, the company has exponentially expanded through implementation of an organic business model and in 2005, due to a period of sustained business growth moved to state-of-the-art laboratories and offices in Reading, UK, as well as opening a new Tokyo office to support our increasing Japanese client base. From these facilities, the company continues to offer services spanning many aspects of drug development with the commitment to exceptional service reflected in our high rate of return business.

In January 2008 PII acquired Pharmaterials providing an enhanced service for our customers.